Analysis of the Compliance of the Vaccination Schedule against Pneumococcal Infection in Young Children

Фельдблюм, И. В.; Bikmieva, A. V.; Захарова, Ю. А.; Ересько, С. С.; Мельник, Е. Н.

doi:10.31631/2073-3046-2018-17-5-111-116

Cited by 5 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…-72,3%) [17]. Известно, что несвоевременное начало противопневмококковой вакцинации увеличивает риск развития ПИ в пер вом полугодии жизни [18,19]. Охват прививками против пневмококковой инфекции взрослого насе ления составил лишь 1,79%, что также не может оказать профилактический эффект на популяцион ном уровне.…”

Section: рисунок 11 динамика заболеваемости взрослых болезнями слуховой (евстахиевой) трубы до начала массовой иммунизации против пи (слеunclassified

Preventive Efficacy of Pneumococcal Conjugated Vaccine (Population Aspects)

Протасова

Фельдблюм

Бахарева³

et al. 2022

Epidemiology and Vaccinal Prevention

Self Cite

View full text Add to dashboard Cite

Relevance. Pneumococcal disease remains an urgent public health problem, despite mass immunization of infants and young children. The impact of children’s universal vaccination on the morbidity and etiological structure in various clinical forms of infection remains unclear in children and adults. Аim. Тo evaluate the herd effect of children’s mass immunization with a 13-valent conjugated pneumococcal vaccine. Materials and Methods. The prophylactic efficacy of mass vaccination is studied within comparative retrospective epidemiological analysis of incidence rates and etiological structure of bacterial meningitis, ear diseases and mastoiditis, and community-acquired pneumonia in children and adults of Krasnoyarsk region in the pre- and post-vaccination periods, according to the official statistics and microbiological monitoring. Results. The changes in decrease of incidence rates with all clinical forms of pneumococcal infection except community-acquired pneumonia are revealed both in children and adults during mass immunization. Etiological structure changes and also changes of S. pneumoniae serotype distribution are detected in major clinical forms of infection. Conclusion. Reducing the incidence rates in children is determined predominantly by vaccinal prevention. The observed decrease of incidence rates in adults is the result of reducing the number of pneumococcal infection sources among children (herd immunity).

show abstract

Preventive Efficacy of Pneumococcal Conjugated Vaccine (Population Aspects)

Протасова

Фельдблюм

Бахарева³

et al. 2022

Epidemiology and Vaccinal Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…низкой массой тела. Реализация массовой стратегии вакцинации в национальной программе иммунизации против пневмококковой инфекции первого года жизни диктует необходимость обеспечения своевременности вакцинации и соблюдения комплаентности схемы иммунизации, что во многом определяет ее эффективность [2,3]. Поскольку вакцины создавались для детей с нормальным сроком гестации, их использование среди недоношенных детей вызывает определенные трудности, как технического, так и психологического характера, не только у родителей, но и у медицинских работников.…”

Section: обоснованиеunclassified

Bronchopulmonary Pathology Prevalence Among Premature infants and Estimation of Prophylactic Efficacy and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Premature infants with Bronchopulmonary Dysplasia

et al. 2020

View full text Add to dashboard Cite

Background. The most frequent chronic lung pathology among infants and especially in premature children with extremely low and very low body weight is bronchopulmonary dysplasia (BPD). The aim of the study is to study the prevalence of bronchopulmonary pathology among premature children and justify the need to vaccinate against pneumococcal disease premature children suffering from BPD. Methods. The official statistics (Form №32) and data from annual reports of the catamnesis department of “the Honourary order” Perm Regional Clinical Hospital were used in order to measure the number of premature children born alive in Perm region in 2015-2017 yy. The estimation of prophylactic efficacy and reactogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) at immunization of premature children with BPD. Results. The study group included vaccinated premature children with BPD (n=29), the experimental group included non-vaccinated premature children with BPD (n=29) and 30 vaccinated term children. Administration of PCV13 in premature children suffering from BPD has revealed its high prophylactic efficacy (no cases of community-acquired pneumonia among vaccinated children during the prospective study for 3 years), high tolerability (no cases of broncho-obstructive syndrome or negative effects on respiratory system such as apnoea or desaturation among vaccinated children). Low reactogenicity (17.2 ± 0.57%) and similar vaccine tolerance with term children (16.5 ± 0.55%) has been revealed as well. The combination of PCV13 with other vaccines from immunisation schedule did not increase the number of vaccine-induced diseases in comparison with administration of PCV13 alone. Conclusion. The scientific necessity of vaccination of premature children with BPD against pneumococcal disease has been proved. The high prophylactic efficacy and low reactogenicity of PCV13 in this children group at tertiary neonatological care (catamnesis department of perinatal center) has been established within the national immunisation schedule.

show abstract

“…Первые результаты эпидемиологической оценки национальной программы иммунизации детей раннего возраста против пневмококковой инфекции были опубликованы в 2017 г. [14][15][16].…”

Section: оригинальные статьиunclassified

“…Как демонстрируют настоящее и ранее проведенные исследования [14][15][16]29], важнейшие показатели эффективности вакцинации против пневмококковой инфекции определяют основные подходы к оценке результативности вакцинации против пневмококковой инфекции, а также систематизированные научные данные мирового опыта применения пневмококковых конъюгированных вакцин. Именно поэтому представляется наиболее важным оценить влияние селективной и массовой стратегии иммунизации детей против пневмококковой инфекции на заболеваемость и смертность от внебольничных пневмоний среди детей в возрасте до 5 лет.…”

Section: резюме основного результата исследованияunclassified

The Effect of Selective and Mass Immunization Against Pneumococcal Infection on the Morbidity and Mortality due to Community-Acquired Pneumonia in Children Under 5 Years of Age

Семериков¹,

Зубова²,

Софронова³

2019

Pediatr. farmakol.

View full text Add to dashboard Cite

Background. It is required to perform estimation of epidemiological and cost efficacy (regarding morbidity rate) of mass routine vaccination against pneumococcal infection in Russian children and carried out earlier selective vaccination of children from high-risk groups on the basis of four-year experience. It is also important to estimate the rate of hospital admissions in this patient group, long-term and annual cycles, morbidity age and etiology structure, and mortality due to community-acquired pneumonia as one of the most common form of pneumococcal disease. The aim is to study the effect of selective and mass immunization against pneumococcal infection on the morbidity and mortality due to community-acquired pneumonia in children under 5 years of age. Methods. The analysis of communityacquired pneumonia morbidity (in 2003–2018) and mortality due to pneumonias (in 2003–2018) in children under the 14 years old in Perm was carried out. Serotypes of circulating pneumococcus, etiology of community-acquired pneumonias and immunization cost efficacy (direct expense on health care) were further studied. The analysis of study indexes was carried out following selective (vaccination of at-risk children in 2011–2014) and mass (vaccination of infants in 2015–2018) immunization strategies. Results. The morbidity rate of community-acquired pneumonias decreased by 4.0 times (from 267.0 to 66.7 for 1000) after performing selective vaccination (2011–2014) in at-risk children (frequently and chronically ill children). The morbidity rate of community-acquired pneumonias in non vaccinated children of the same group increased by 2.0 times (from 40.0 to 80.0 for 1000 non-vaccinated). The prophylactic efficacy index was 46.0. Whereby the antibacterial index among vaccinated frequently and chronically ill children was 0.11 on one child. This index has decreased by 2.6 times (from 0.11 to 0.04 on one child) in a year within the framework of prospective controlled randomized clinical study. The antibacterial index among non-vaccinated children of this group remained slightly the same: 0.09 and 0.12 respectively. During the selective vaccination the mortality rate among infants decreased by 2 times: long-term average index was 17.9 (2011–2014) against 35.2 (2003-2010) on 100 thousand children. Mass vaccination of infants against pneumococcal infection has reduced the incidence of community-acquired pneumonias among children under 2 years of age and has led to absence of multiple sites of pneumococcal infection in children’s organizations. It also has reduced the number of hospitalized children and achieved zero mortality due to pneumonias in infants by the third year of this immunization strategy implementation. The obtained results were achieved mainly due to circulation of 7 pneumococcal serotypes (6A, 6B, 9V, 14, 19A, 19F, 23F) in children under 5 years of age. The threshold level of vaccination against pneumococcal infection advancing morbidity and mortality due to pneumonias in children was specified. The strategy of mass vaccination of infants was cost-effective. Conclusion. The new data on epidemiological and cost efficacy of various immunization strategies against pneumococcal infection in children was obtained.

show abstract

Analysis of the Compliance of the Vaccination Schedule against Pneumococcal Infection in Young Children

Cited by 5 publications

References 6 publications

Preventive Efficacy of Pneumococcal Conjugated Vaccine (Population Aspects)

Preventive Efficacy of Pneumococcal Conjugated Vaccine (Population Aspects)

Bronchopulmonary Pathology Prevalence Among Premature infants and Estimation of Prophylactic Efficacy and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Premature infants with Bronchopulmonary Dysplasia

The Effect of Selective and Mass Immunization Against Pneumococcal Infection on the Morbidity and Mortality due to Community-Acquired Pneumonia in Children Under 5 Years of Age

Contact Info

Product

Resources

About